Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Herrera, Carmen ^a   Holberton, J ^b   Davis, P ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Ductus arteriosus, patent *drug therapy; mortality ; Indomethacin administration dosage; *therapeutic use ; Infant, newborn; Infant, premature; Infant, premature, diseases *drug therapy

Indexed keywords

CREATININE; INDOMETACIN;

ARTIFICIAL VENTILATION; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CHILD CARE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFECT; ECHOCARDIOGRAPHY; HUMAN; KIDNEY DISEASE; LENGTH OF STAY; LIGATION; NECROTIZING ENTEROCOLITIS; OXYGEN SUPPLY; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RETINOPATHY; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE VOLUME;

EID: 44949155402     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003480.pub3     Document Type: Review

References (30)

1. Hammerman 1990 {published data only} Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. Journal of Pediatrics 1990;117:771-6.
2. Lee 2003 {published data only} Lee J, Rajadurai VS, Tan KW, Wong KY, Wong EH, Leong JY. Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics 2003;112:345-50.
3. Rennie 1991 {published data only} Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Archives of Disease in Childhood 1991;66:55-8.
4. Rhodes 1988 {published data only} Rhodes PG, Ferguson MG, Reddy NS, Joransen JA, Gibson J. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. European Journal of Pediatrics 1988;147:481-4.
5. Tammela 1999 {published data only} Tammela O, Ojala R, Iivainen T, Lautamatti L, Pokela M, Janas M, et al.Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. Journal of Pediatrics 1999;134:552-7.
6. VanOvermeire 2001 Van Overmeire B, Rienstra M, De Groore K. Short versus prolonged indomethacin therapy for retreatment of patent ductus arteriosus in preterm infants. Pediatric Research 2001;49:375 A.
7. Bell 1978 Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187:1-7.
8. Brook 1995 Brook M, Heymann M. Patent ductus arteriosus. In: EmmanouilidesGC, RiemenschneiderTA, AllenHD, GutgesellHP editor(s). Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult. Williams & Wilkins, 1995:746-4.
9. Clyman 1996 Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. Journal of Pediatrics 1996;128:601-7.
10. Cotton 1978 Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriousus. Journal of Pediatrics 1978;92:467-73.
11. Friedman 1976 Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. New England Journal of Medicine 1976;295:526-9.
12. Gersony 1983 Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin on premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics 1983;102:895-906.
13. Hammerman 1995 Hammerman C. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology 1995;22:457-79.
14. Heymann 1976 Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. New England Journal of Medicine 1976;295:530-3.
15. Itabashi 2003 Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patent ductus arteriosus and subsequent renal abnormalities in preterm infants treated with indomethacin. Journal of Pediatrics 2003;143:203-7.
16. Kluckow 2000 Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow and pulmonary hemorrhage. Journal of Pediatrics 2000;137:68-72.
17. Papile 1978 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics 1978;92:529-34.
18. Qinn 2002 Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics 2002;110:e10.
19. Rojas 1995 Rojas M, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. Journal of Pediatrics 1995;126:605-10.
20. Schmidt 2001 Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts R, Saigal S, et al.Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. New England Journal of Medicine 2001;344:1966-72.
21. Seyberth 1982 Seyberth HW, Muller H, Wille L, Pluckthun H, Wolf D, Ulmer HE. Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. Pediatric Pharmacology 1982;2:127-41.
22. Seyberth 1983 Seyberth HW, Knapp G, Wolf D, Ulmer HE. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. European Journal of Pediatrics 1983;141:71-6.
23. Shaffer 2002 Shaffer CL, Gal P, Ransom JL, Carlos RQ, Smith MS, Davey AM, Dimaguila MA, Brown YL, Schall SA. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Critical Care Medicine 2002;30:343-8.
24. Siassi 1976 Siassi B, Blanco C, Cabal L, Coran A. Incidence and clinical features of patent ductus arteriosus in low birthweight infants: a prospective analysis of 150 consecutively born infants. Pediatrics 1976;57:347-51.
25. Sinclair 1992 Sinclair JC, Bracken MB. Effective care of the newborn infant. Oxford, Oxford University Press, 1992.
26. Walters 1988 Walters M. Tolerance of intravenous indomethacin treatment for premature infants with patent ductus arteriosus. BMJ 1988;297:773-4.
27. Yaffe 1980 Yaffe SJ, Friedman WF, Rogers D, Lang P, Ragni M, Saccar C. The disposition of indomethacin in preterm babies. Journal of Pediatrics 1980;97:1001-6.
28. Yeh 1983 Yeh T, Luken J, Raval D, Thalji A, Carr I, Pildes R. Indomethacin treatment in small versus large premature infants with ductus arteriosus. Comparison of plasma indomethacin concentration and clinical response. British Heart Journal 1983;50:27-30.
29. Yeh 1991 Yeh TF, Carr I. Pharmacologic closure of ductus arteriosus. Drug Therapy in the Neonate and Small Infant. 2nd Edition. Chicago: Year Book, 1991:123-38.
30. Herrera 2004 Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD003480. DOI:10.1002/14651858.CD003480.pub3.